Leonard Green & Partners’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Leonard Green & Partners’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-2,150,000	Closed	-$10.7M	–	59
2020 Q4	$10.7M	Buy	2,150,000 +1,650,000	+330%	+$3.51M	0.15%	14
2020 Q3	$1.13M	Buy	+500,000	New	+$1.43M	0.06%	28
2020 Q1	–	Sell	-70,000	Closed	-$211K	–	48
2019 Q4	$211K	Buy	+70,000	New	+$182K	0.05%	33

Other funds holding BMY.RT

JCI

Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return

Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return

TNB

Thomasville National Bank Thomasville, Georgia $1.82B AUM

WAM

Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return

IAIM

International Assets Investment Management Orlando, Florida $1.67B AUM 28.26% 1-Year Est. Return

Leonard Green & Partners's BMY.RT Position: Q1 2021 in Review

Leonard Green & Partners sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 2,150,000 shares — an estimated $10.7M sold.

Leonard Green & Partners first reported a position in BMY.RT in Q4 2019 and held it in 3 quarters. The position peaked at $10.7M in Q4 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

Leonard Green & Partners reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
Leonard Green & Partners sold 2,150,000 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $10.7M.
Leonard Green & Partners first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 3 quarters.
Leonard Green & Partners's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $10.7M in Q4 2020.
12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Leonard Green & Partners's 13F filing for Q1 2021, filed 17 May 2021.